PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Real-world treatment patterns in advanced pancreatic neuroendocrine tumors in the era of targeted therapy: perspectives from an academic tertiary center and community oncology practices.

Abstract Pancreatic neuroendocrine tumors (pNETs) are rare, slow-growing cancers. Optimal treatment of advanced pNETs is unclear. The aim of this study was to examine treatment patterns and preferences among an academic tertiary medical center and community-based oncology practices. Retrospective chart review was performed for patients with newly diagnosed locally advanced, metastatic, or unresectable pNET diagnosed between January 2010 and December 2013 at an academic tertiary cancer center [University of California, San Francisco (UCSF)] or a large network of community oncology practices [Altos Solutions' OncoEMR database (ALTOS)]. Fifty-four eligible patients (N UCSF = 23; N ALTOS = 31) were identified. Median time to treatment initiation was 1.1 months; median follow-up time was 22.9 months. UCSF patients underwent more lines of therapy than ALTOS patients despite similar follow-up times. UCSF tended toward more invasive treatment than ALTOS. The median time to treatment discontinuation was statistically significantly shorter for patients on chemotherapy than on targeted therapy in the combined UCSF and ALTOS groups (chemotherapy = 2.1 months vs. targeted = 18.6 months, p < 0.001). Treatment patterns and duration for newly diagnosed advanced pNETs vary widely both within and between different practice settings. Further studies are warranted to investigate the significant difference in duration of targeted therapy compared to chemotherapy.
PMID
Related Publications

Surgery in malignant pancreatic neuroendocrine tumors.

Metastatic Pancreatic Adenocarcinoma Treatment Patterns, Health Care Resource Use, and Outcomes in France and the United Kingdom Between 2009 and 2012: A Retrospective Study.

Observational study of natural history of small sporadic nonfunctioning pancreatic neuroendocrine tumors.

Trends in Receipt and Timing of Multimodality Therapy in Early-Stage Pancreatic Cancer.

A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.

Authors

Mayor MeshTerms
Keywords

Advanced pancreatic neuroendocrine tumors

Low-grade neuroendocrine tumor

Targeted therapy

Treatment pattern

Journal Title medical oncology (northwood, london, england)
Publication Year Start




PMID- 28393314
OWN - NLM
STAT- MEDLINE
DA  - 20170410
DCOM- 20170419
LR  - 20170419
IS  - 1559-131X (Electronic)
IS  - 1357-0560 (Linking)
VI  - 34
IP  - 5
DP  - 2017 May
TI  - Real-world treatment patterns in advanced pancreatic neuroendocrine tumors in the
      era of targeted therapy: perspectives from an academic tertiary center and
      community oncology practices.
PG  - 88
LID - 10.1007/s12032-017-0927-0 [doi]
AB  - Pancreatic neuroendocrine tumors (pNETs) are rare, slow-growing cancers. Optimal 
      treatment of advanced pNETs is unclear. The aim of this study was to examine
      treatment patterns and preferences among an academic tertiary medical center and 
      community-based oncology practices. Retrospective chart review was performed for 
      patients with newly diagnosed locally advanced, metastatic, or unresectable pNET 
      diagnosed between January 2010 and December 2013 at an academic tertiary cancer
      center [University of California, San Francisco (UCSF)] or a large network of
      community oncology practices [Altos Solutions' OncoEMR database (ALTOS)].
      Fifty-four eligible patients (N UCSF = 23; N ALTOS = 31) were identified. Median 
      time to treatment initiation was 1.1 months; median follow-up time was 22.9
      months. UCSF patients underwent more lines of therapy than ALTOS patients despite
      similar follow-up times. UCSF tended toward more invasive treatment than ALTOS.
      The median time to treatment discontinuation was statistically significantly
      shorter for patients on chemotherapy than on targeted therapy in the combined
      UCSF and ALTOS groups (chemotherapy = 2.1 months vs. targeted = 18.6 months, p &lt; 
      0.001). Treatment patterns and duration for newly diagnosed advanced pNETs vary
      widely both within and between different practice settings. Further studies are
      warranted to investigate the significant difference in duration of targeted
      therapy compared to chemotherapy.
FAU - Herring, Maurice
AU  - Herring M
AD  - UCSF Helen Diller Family Comprehensive Cancer Center, 550 16th St., Box 3211, San
      Francisco, CA, 94143, USA.
FAU - Huynh, Lynn
AU  - Huynh L
AD  - Analysis Group Inc., Boston, MA, USA.
FAU - Duh, Mei Sheng
AU  - Duh MS
AD  - Analysis Group Inc., Boston, MA, USA.
FAU - Vekeman, Francis
AU  - Vekeman F
AD  - Analysis Group Inc., Boston, MA, USA.
FAU - Tiew, Audrey
AU  - Tiew A
AD  - Analysis Group Inc., Boston, MA, USA.
FAU - Neary, Maureen
AU  - Neary M
AD  - Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
FAU - Bergsland, Emily
AU  - Bergsland E
AUID- ORCID: http://orcid.org/0000-0001-7754-6552
AD  - UCSF Helen Diller Family Comprehensive Cancer Center, 550 16th St., Box 3211, San
      Francisco, CA, 94143, USA. [email protected]
LA  - eng
PT  - Journal Article
DEP - 20170409
PL  - United States
TA  - Med Oncol
JT  - Medical oncology (Northwood, London, England)
JID - 9435512
SB  - IM
MH  - Academic Medical Centers/statistics &amp; numerical data
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Cancer Care Facilities/statistics &amp; numerical data
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Molecular Targeted Therapy
MH  - Neuroendocrine Tumors/*therapy
MH  - Pancreatic Neoplasms/*therapy
MH  - Practice Patterns, Physicians'/statistics &amp; numerical data
MH  - Retrospective Studies
MH  - Tertiary Care Centers/statistics &amp; numerical data
MH  - Young Adult
OTO - NOTNLM
OT  - Advanced pancreatic neuroendocrine tumors
OT  - Low-grade neuroendocrine tumor
OT  - Targeted therapy
OT  - Treatment pattern
EDAT- 2017/04/11 06:00
MHDA- 2017/04/20 06:00
CRDT- 2017/04/11 06:00
PHST- 2017/02/20 [received]
PHST- 2017/03/21 [accepted]
AID - 10.1007/s12032-017-0927-0 [doi]
AID - 10.1007/s12032-017-0927-0 [pii]
PST - ppublish
SO  - Med Oncol. 2017 May;34(5):88. doi: 10.1007/s12032-017-0927-0. Epub 2017 Apr 9.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>